FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

1. Name and Address of Reporting Person^* **BioImpact Capital LLC**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

> > 7. Nature of Indirect Beneficial Ownership (Instr. 4)

See Footnote⁽⁵⁾

See Footnote⁽⁸⁾

11. Nature of Indirect Beneficial Ownership (Instr. 4)

1. Name and Address of Reporting Person's GADICKE ANSBERT 2. Issuer Name and Ticker or Trading Symbol i Teos Therapeutics, Inc. [ITOS] 3. Date of Earliest Transaction (Month/Day/Year) 09/28/2021 4. If Amendment, Date of Original Filed (Month/Day/Year) 09/28/2021 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities (e.g., puts, calls, warrants, options, convertible Securities) Table II - Derivative Securities (e.g., p	Instruc	ction 1(b).			File	d pursu	lant to	Section	า 16(a	ι) of the	e Secu	rities Exchang	e Act o	f 1934					
Common Stock			f Reporting Person	·*		or S	Section	30(h) c	of the	Investr	nent C	company Act o			. Relationshi	o of Repo	rting Pe	erson(s)	to Issuer
Common Stock Comm	· · ·											(0	(Check all applicable)						
COMMINICALITIAL 480 KENDALL STREET 480 KENDAL				-															
Common Stock						3. Date of Earliest Transaction (Month/Day/Year) below) below) below)									ow)				
A Amendment, Date of Original Field (Month/Day/Year) Cambridge Cambrid							20,20												
CAMBRIDGE MA	450 KEI	NDALL ST	REET			4. If	Amen	dment,	Date	of Orig	inal Fi	led (Month/Da	y/Year)			r Joint/Gr	oup Fili	ng (Ched	k Applicable
City City	l ` ′														,	filed by C	One Re	porting P	erson
Table Non-Derivative Security (Instr. 3) Security Security Security (Instr. 3) Security Sec	CAMBRIDGE MA 02142															More th	an One F	Reporting	
1. Title of Security (Instr. 3)	(City)	(S	tate)	(Zip)															
Date Common Stock			Table	e I - N	lon-Deriva	ative	Secu	ırities	S Ac	quire	d, Di	sposed of	, or B	enefic	ially Own	ed			
Common Stock	Date			Exec (Year) if any		ecution Date, ny		Transaction [Code (Instr. 5		Disposed Of (D) (Instr. 3,			Securitie Benefici	Securities Beneficially		: Direct Indirect	Beneficial		
Common Stock							•		,		v	Amount	(A) oi (D)	Price	Reported Transaction(s)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible) Little of Derivative Conversion Security (instr. 3) and 4) Little of Derivative Security (instr. 4) Little	Common	Stock			09/28/20)21				S ⁽¹⁾		32,154(2)(3)	D	\$270	/(4) 5397803			See Footnote	
1. Title of Date (Bost) and Conversion (Instr. 3) and Address of Reporting Person* GABRIDGE MA 02142 (City) (State) (City) (State) (City) (First) (Middle) (City) (First) (Middle) (Middle) (City) (First) (Middle) (Middle) (Middle) (City) (First) (Middle) (Middle) (City) (First) (Middle) (Middle) (Middle) (City) (First) (Middle) (Middle) (City) (First) (Middle) (Middle) (Middle) (Middle) (City) (Middle) (Common	Stock			09/30/20)21				S ⁽¹⁾		3,836 ⁽⁶⁾	D	\$27()'/(/) 5.393.96 ⁷ /			See Footnote	
1. Title of Derivative Privative Private			Ta	able I												d	ļ		
Security (Instr. 3) Provided (Instr. 4) Provided (Instr. 5) Provided (Instr. 4) Provid	1. Title of	2.	3. Transaction	3A. I		_	alis,	_		_					_	9. Numb	er of	10.	11. Nat
1. Name and Address of Reporting Person* GADICKE ANSBERT (Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Street) Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Street) Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	Security	or Exercise Price of Derivative	xercise (Month/Day/Year) e of vative) if an	y ,	Code		Securities Acquired (A) or Disposed of (D)		Expiration I (Month/Day			Securities Underlying Derivative Security (Instr.		Security	Securities Beneficially Owned Following Reported Transaction(s)	es ally ig d tion(s)	Form: Direct (D) or Indirect (I) (Instr. 4)	Benefic O) Owners ect (Instr. 4
1. Name and Address of Reporting Person* GADICKE ANSBERT (Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Sireet) CAMBRIDGE MA 02142 (Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Sireet) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) COMPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142							_							Amount		(111501.4)			
1. Name and Address of Reporting Person* GADICKE ANSBERT (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) (Street) CAMBRIDGE MA 02142						Code	·	(A)	(D)				Title	or Number of					
GADICKE ANSBERT (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	1. Name a	nd Address o	f Reporting Persor	<u> </u> n*		10000		10.9	(-)	1 = 1.01		7 24.0		0.14.00				<u> </u>	
C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142																			
C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	(1 aat)		(Firet)		'A 4; dalla \		-												
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142		M CAPITA	,	((Middle)														
CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142																			
CAMBRIDGE MA 02142 (City) (State) (Zip) 1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	(Ctroot)						-												
1. Name and Address of Reporting Person* UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	l ` ′	RIDGE	MA	(02142														
UBS Oncology Impact Fund L.P. (Last) (First) (Middle) C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	(City)		(State)	((Zip)														
C/O MPM CAPITAL 450 KENDALL STREET (Street) CAMBRIDGE MA 02142	ı																		
450 KENDALL STREET (Street) CAMBRIDGE MA 02142	(Last)		(First)	((Middle)														
CAMBRIDGE MA 02142																			
(City) (State) (Zip)		RIDGE	MA	(02142														
	(City)		(State)	((Zip)		-												

(Last)	(First)	(Middle)						
C/O MPM CAPITAL								
450 KENDALL STREET								
(Street)								
CAMBRIDGE	MA	02142						
(City)	(State)	(Zip)						
Name and Address of Reporting Person* Oncology Impact Fund (Cayman) Management L.P.								
(Last)	(First)	(Middle)						
C/O MPM CAPITAL								
450 KENDALL STREET								
(Street)								
(Street) CAMBRIDGE	MA	02142						

Explanation of Responses:

- 1. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
- 2. The shares were sold as follows: 11,447 by MPM BioVentures 2014, L.P. ("BV 2014"), 394 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 7,230 by MPM BioVentures 2018, L.P. ("BV 2018"), 143 by MPM Asset Management Investors BV2018 LLC ("AM BV2018") and 12,940 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC.
- 3. BioImpact Capital LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is a managing partner of BioImpact. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.95 to \$27.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. The shares are held as follows: 1,864,079 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,160 by AM BV2014, 1,177,311 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)"), 23,235 by AM BV2018 and 2,107,092 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- 6. The shares were sold as follows: 1,366 by BV 2014, 47 by AM BV2014, 862 by BV 2018, 17 by AM BV2018 and 1,544 by UBS Oncology.
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$26.955 to \$27.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 8. The shares are held as follows: 1,862,713 by BV 2014, 107,713 by BV 2014(B), 64,113 by AM BV2014, 1,176,449 by BV 2018, 54,213 by BV 2018(B), 23,218 by AM BV2018 and 2,105,548 by UBS Oncology. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.

Remarks:

/s/ Ansbert Gadicke 09/30/2021 /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund 09/30/2021 (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P /s/ Ansbert Gadicke, managing partner of BioImpact Capital 09/30/2021 /s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of 09/30/2021 Oncology Impact Fund (Cayman) Management L.P. ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.